EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

Completed · Phase 2

Conditions studied: Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer

In brief

This phase II trial is studying how well EF5 works in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer. Diagnostic procedures using the drug EF5 to find oxygen in tumor cells may help in planning cancer treatment

Key facts

Study ID

NCT00107445

Run by

National Cancer Institute (NCI)

People needed

60

Starts

2005-02-01

Last updated by the study team

2013-01-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed* diagnosis of 1 of the following:
• Cervical cancer
• Ovarian epithelial cancer
• Endometrial cancer
• Peritoneal cavity cancer
• Requires surgery or biopsy for diagnosis or as standard initial treatment for the tumor
• Performance status - ECOG 0-2
• WBC ≥ 2,000/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Bilirubin normal
• Creatinine normal
• Creatinine clearance ≥ 60 mL/min
• No significant cardiac condition that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 month after study participation
• Weight ≤ 130 kg
• No other significant medical condition that would preclude study participation
• No scheduled chemotherapy for the tumor within the past 3 months
• No scheduled radiotherapy to the tumor within the past 3 months
• No other concurrent investigational agents

Where it is running

• Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.